Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM.
Simon GR, et al. Among authors: eiseman ia.
Clin Cancer Res. 2006 Aug 1;12(15):4645-51. doi: 10.1158/1078-0432.CCR-05-2379.
Clin Cancer Res. 2006.
PMID: 16899614
Clinical Trial.